氩氦刀冷冻消融联合动脉栓塞治疗肾癌的临床研究  

Clinical efficacy of argon-helium cryoablation combined with transcatheter renal artery embolization for renal carcinoma

作　　者：李炯[1,2] 张欣贤 袁磊[2] 许健[2] 

机构地区：[1]徐州市儿童医院,江苏徐州221006 [2]南京军区南京总医院医学影像科,江苏南京210002

出　　处：《中医学报》2014年第B12期461-462,共2页Acta Chinese Medicine

摘　　要：目的探讨冷冻消融联合肾动脉栓塞（ transcatheter renal artery embolization TRAE）治疗肾癌的安全性及疗效.方法：回顾性分析2007 年1 月～2013 年6 月在我院行冷冻消融联合TRAE 治疗的56 例肾癌患者的临床资料.观察治疗前后肾功能、T 细胞亚群、靶病灶的影像学（CT 或MR）等指标的变化及中位生存期、生存率动态随访监测,以评价联合方案的临床疗效.结果：术后1 周内复查肾功能（尿素氮、尿酸和肌酐）与术前比较：二者差异无统计学意义（P〉0.05）,监测T 细胞亚群发现CD3＋、CD4＋、CD4/＋CD8＋比术前增高,CD8＋、Treg 比术前降低,二者差异有统计学意义（P〈0.01）.联合治疗患者中位生存期为26 个月,12、24、36 个月的生存率分别为：94.6%、57.1%、26.7%.结论：冷冻消融联合TRAE 治疗肾癌是一种安全、有效,值得临床推广应用的方法.ObjectiveTo evaluate the safety and efficacy of argon-helium cryoablation combined with transcatheter renal artery embolization （TRAE） for the treatment of renalcarcinoma. Methods：Retrospective analysis of January 2007 to June 2013 in our hospital argon-helium cryoablation combined with transcatheter renal artery embolization for 56 casesof RCC patients with clinical data. At pre-and post-treatment, kindney function and tumor diameter（computed tomography or magnetic resonance imaging）were observed.and themedian survival, the survival rate was dynamically follow-up monitoring.And the clinical efficacy of joint programs were assessed. Results：There was no significant change of kidneyfunction at pre-and post-treatment（P〉0.05）,The percertages of CD3＋T,CD4＋T,CD4＋T/CD8＋T were significantly increased （P 〈0.01） and the percertages of CD8＋T,Treg were decreased（P〈0.01）.The median survival duration of the TRAE＋cryoablation was 26 month. 12,24,36-month survival rates were： 94.6%, 57.1%, 26.7%. Conclusions：Argon-helium cryoablationcombined with TRAE for the treatment of renal carcinoma is safe and effective, which is worthy to spread in clinical application.

关 键 词：肾癌 冷冻消融 栓塞 临床疗效 

分 类 号：R73-3[医药卫生—肿瘤]